BioSpace News Archive

Fourth-quarter reported net sales increased 21.4 percent year-over-year to $1.56 billion, and internal sales increased 23.5 percent. Fourth-quarter GAAP earnings of $0.30 per diluted share and adjusted earnings per share of $0.38 per diluted share.

Samsung Biologics, a global contract development and manufacturing organization, celebrated the one-year mark of Live Virtual Tour, a real-time interactive platform to provide remote site inspections for both clients and regulatory agencies.

Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).

Cytokinetics, Incorporated today announced three presentations at Heart Failure 2021, an International Congress of the European Society of Cardiology taking place online from June 29, 2021 – July 1, 2021.

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that Dr. Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination to the Supervisory Board.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced a comprehensive update on its discovery and clinical-stage pipeline at its 2021 virtual R&D Day

Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced data from its three clinical-stage core inhibitor programs, vebicorvir (VBR or ABI-H0731), ABI-H2158 (2158), and ABI-H3733 (3733), in an oral presentation and two poster presentations during the International Liver Congress™ 2021, the Annual Meeting of the European Association for the Study of the Liver (EASL),

Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox®, the Company’s proprietary heat-activated liposomal encapsulation of doxorubicin.

According to Transparency Market Research, the global endometrial ablation market is foreseen to exhibit a steady CAGR of 5.50% within the forecast period from 2016 to 2024.

Photocure, The Bladder Cancer Company, announces the publication of a study in the journal Urologic Oncology.